Valdés TGE, Martínez BME, Morayta RCARR

Idioma: Español
Referencias bibliográficas: 22
Paginas: 49-56
Archivo PDF: 1003.53 Kb.

RESUMEN

La mucormicosis es una infección por hongos oportunistas del orden mucorales y tercera causa de infección fúngica invasiva, es de baja incidencia, pero alta mortalidad (50-90%), generalmente se manifiesta en huéspedes inmunocomprometidos. Se adquiere por inhalación, ingestión y/o contaminación de heridas de esporangiosporas que se encuentran en el medio ambiente. La principal presentación clínica en niños es la rinoorbitocerebral. El pilar fundamental en el pronóstico es la sospecha, el inicio de terapia fúngica anticipada y el desbridamiento del tejido necrótico. Presentamos serie de tres casos de niños con enfermedad hematológica e inmunosupresión secundaria con mucormicosis, forma diagnóstica, tratamiento y desenlace.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kung HC, Huang PY, Chen WT, Ko BS, Chen YC, Chang SC, et al. 2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan. J Microbiol Immunol Infect. 2018; 51 (1): 1-17.

2. Carrillo-Rodríguez VM, Soto-Ramos M, Hernández-Saldaña R, Hinojos-Gallardo LC, González-Ortiz S. Mucormicosis pulmonar en niños. Presentación de 3 casos y revisión de la literatura. Neumol Cir Torax. 2017; 76 (2): 96-101.

3. Imbernón A, Agud JL, Cuétara MS, Casqueiro JC, Nuñez P, Domínguez AR et al. Successful therapy of progressive rhino-orbital mucormycosis caused by Rhizopus arrhizus with combined and sequential antifungal therapy, surgery and hyperbaric therapy. Med Mycol Case Rep. 2014; 6: 51-54.

4. Valdez-Geraldo CM, Zavala-Ruiz MG, Collado-Castro I, Ramírez-Villela C, Olguín A. Mucormicosis rinocerebral: Reporte de caso en escolar con cetoacidosis diabética. Rev Mex Neuroci. 2014; 15 (4): 229-233.

5. Danion F, Aguilar C, Catherinot E, Alanio A, DeWolf S, Lortholary O et al. Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med. 2015; 36 (5): 692-705.

6. Alemayehu T. Rhino-orbito-cerebral mucormycosis: neglected mycoses in childhood malignancies. Virol-mycol. 2017; 6 (2).

7. Bravo JH, Agudelo AM, Cortés A, Matta L. Mucormicosis rino-órbito-cerebral de origen dental. Biomédica. 2018; 38 (1): 27-31.

8. Mutchnick S, Soares D, Shkoukani M. To exenterate or not? An unusual case of pediatric rhinocerebral mucormycosis. Int J Pediatr Otorhinolaryngol. 2015; 79 (2): 267-270.

9. Pana ZD, Seidel D, Skiada A, Groll AH, Petrikkos G, Cornely OA et al. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis. 2016; 16 (1): 667.

10. Jensen TSR, Arendrup MC, von Buchvald C, Frandsen TL, Juhler M, Nygaard U. Successful treatment of rhino-orbital-cerebral mucormycosis in a child with leukemia. J Pediatr Hematol Oncol. 2017; 39 (4): e211-e215.

11. Tortorano AM, Richardson M, Roilides E, van Diepeningen A, Caira M, Munoz P et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014; 20 Suppl 3: 27-46.

12. Asano-Mori Y. Diagnosis and treatment of mucormycosis in patients with hematological malignancies. Med Mycol J. 2016; 57 (4): J155-J162.

13. Millon L, Larosa F, Lepiller Q, Legrand F, Rocchi S, Daguindau E et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin Infect Dis. 2013; 56 (10): e95-101.

14. Abela L, Toelle SP, Hackenberg A, Scheer I, Güngör T, Plecko B. Fatal outcome of rhino-orbital-cerebral mucormycosis due to bilateral internal carotid occlusion in a child after hematopoietic stem cell transplantation. Pediatr Infect Dis J. 2013; 32 (10): 1149-1150.

15. Chamdine O, Gaur AH, Broniscer A. Effective treatment of cerebral mucormycosis associated with brain surgery. Pediatr Infect Dis J. 2015; 34 (5): 542-543.

16. Chitasombat MN, Kontoyiannis DP. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents. Curr Opin Infect Dis. 2016; 29 (4): 340-345.

17. Drogari-Apiranthitou M, Mantopoulou FD, Skiada A, Kanioura L, Grammatikou M, Vrioni G et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother. 2012; 67 (8): 1937-1940.

18. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007; 51 (7): 2587-290.

19. Vitale RG, de Hoog GS, Schwarz P, Dannaoui E, Deng S, Machouart M et al. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol. 2012; 50 (1): 66-75.

20. Pagano L, Cornely OA, Busca A, Caira M, Cesaro S, Gasbarrino C et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013; 98 (10): e127-e130.

21. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016; 22 (9): 811.e1-811.e8.

22. Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013; 98 (4): 492-504.